Antiretroviral prevention methods are not in competition,
and policy makers and providers need to start to thinking about how
antiretrovirals, pre-exposure prophylaxis and microbicides will be provided as part
of a combination prevention package – and who will benefit most from each method,
delegates heard at a satellite meeting on the opening day of the Sixth
International AIDS Society Conference (IAS 2011) in Rome.
“You don’t want to have the family planning clinic here, the
pills clinic here, the injections clinic here, and the microbicides clinic over
here,“ said Dr Stephen Becker of the Bill and Melinda Gates Foundation.
Delegates were discussing the rapidly changing landscape of
HIV prevention methods that use antiretroviral drugs. One year ago, at the
International AIDS Conference in Vienna, the world heard the results of the
CAPRISA study, which showed that a microbicide gel containing tenofovir halved
the risk of HIV infection in women who used the vaginal gel consistently.
Since then results from four studies have added to the array
of prevention methods that exploit antiretroviral drugs to prevent transmission
or acquisition of HIV infection:
- The iPrEx study showed that taking the
antiretroviral combination Truvada
(tenofovir and emtricitabine (also known as FTC) reduced the risk of HIV
infection in men who have sex with men by 44%.
- The HPTN 052 study showed that early treatment
reduced the risk of HIV transmission to an uninfected regular partner by at
- The Partners study showed pre-exposure
prophylaxis with Truvada or with
tenofovir alone reduced the risk of HIV infection by between 62% and 73%.
- The TDF2 study showed that pre-exposure prophylaxis with Truvada reduced the risk of infection by
between 62% and 78%.
“We need to reach out to women who don’t perceive themselves to be at risk", Samu Dube
The first tenofovir-containing microbicide could receive
regulatory approval by the end of 2013, subject to positive results from a
confirmatory trial now taking place in South Africa. That study is testing
exactly the same dosing regimen as that used in the CAPRISA study, the
so-called BAT 24 dosing schedule: one dose Before, one After, and no more than
Two doses in 24 hours.
A second CAPRISA study (008) is testing the roll-out of
tenofovir gel through family planning clinics in KwaZulu-Natal, comparing the
monthly testing and follow-up schedule used in the original CAPRISA study with
a three-monthly schedule, in order to examine the feasibility and acceptability
of providing a microbicide through existing health services that target
sexually active women.
Although the South African government has already begun
investing in the scale-up of production facilities to manufacture the gel, the
extent of demand for the microbicide is still unclear. Studies of women’s’
attitudes towards the microbicide will be needed to gauge demand, but a lot of
work will also be needed to develop demand – and to make sure that women
understand how they could benefit from using the microbicide.
“We need to reach out to women who don’t perceive themselves
to be at risk, and we should be getting communities to rally round to be early
adopters of tenofovir gel,” said Samu Dube of the Global Campaign for
“We need to get the product to the places where women are:
the family planning clinics, the immunisation centres, antenatal clinics. We
also need to target the school health system.”
However, work will also be needed to convince the providers
of those services that they have a role to play in expanding women’s
opportunities to protect themselves from HIV infection.
“Providers can be major gatekeepers – their attitudes and how they present it to women will be critical", Catherine Hankins
“Providers can be major gatekeepers – their attitudes and
how they present it to women will be critical. We saw very negative attitudes
from the providers towards the female condom. Ideally they should use [the
microbicide] themselves at least once,” said Catherine Hankins of UNAIDS.
Provider and donor preferences for particular prevention
methods could also overshadow the need to think about prevention technologies
as a spectrum of methods that will suit different people at different times.
“Is treatment always the best option [as the prevention
measure] in the serodiscordant couple? If the index partner can’t or won’t take
pills, or if the HIV-negative partner is having concurrent partners, they might
need PrEP or a microbicides,” said Professor Myron Cohen of the University of
North Carolina, lead investigator on the HPTN 052 study.
He also pointed to the estimated volume of transmission that
takes place during the early weeks after infection. In the region of Malawi in
which the HPTN 052 study recruited participants, his team calculated that
around 30% of HIV infections came from undiagnosed people who had been infected
less than six months previously.
In these circumstances, he pointed out, a microbicide or
PrEP would still have an important role to play, even if counselling, testing,
early diagnosis and treatment could be maximised.
Indeed, defining the niches of different antiretroviral-based
prevention methods will depend on up to date information about local epidemics
and behavioural patterns, applied through mathematical modelling to generate
options for policy makers, what Willard Cates of Family Health International
called “the science of prioritisation, to make scarce resources go further to
“Modellers have their hands full at the moment, and that’s
for good reason. That information needs to go out now [in order to help with
prioritisation],” said Peter Cherutich of the Kenyan Ministry of Health.
“It’s very important not to pit prevention technologies against each other,” Renée Ridzon
“It’s very important not to pit prevention technologies
against each other,” said Renée Ridzon of the Bill and Melinda Gates
However, microbicides may have unique introductory
challenges, said David Stanton of USAID, whose agency is strongly committed to
supporting microbicide scale-up in sub-Saharan Africa. The tenofovir
microbicide will have to clear the hurdles of confirmatory trials, as well as differences in
regulatory requirements between countries before it can even be distributed. The
South African Medicines Control Agency has not yet given a clear opinion on
what data it will require for registration, leaving the danger that further
studies could be needed to achieve registration in South Africa.
There is also the challenge of ensuring that the gel is
manufactured to a consistently high standard, so that contains the right
quantity of tenofovir in each dose, and the challenge of organising an
efficient distribution system.
WHO and UNAIDS are working with CONRAD and the South African
Ministry of Science and Technology, two of the sponsors of the satellite
meeting, to plan for introduction of tenofovir gel, and WHO will develop
guidance on use of the microbicide so that it can be released as soon as the
first regulatory approval is granted.
Global Campaign for Microbicides, the third sponsor of the
meeting, is working to raise awareness of the choices around prevention
technologies, both for policy makers and communities, and to build community
awareness and demand for the tenofovir microbicide.
But perhaps the biggest challenge for introduction will be
the accessibility of the microbicide gel for a group at particularly high risk
of infection in southern Africa – young women and girls. Dr. Sengiziwe Sibeko,
a women’s health practitioner in KwaZulu-Natal, said that sexually active
adolescent girls represented an important group who could benefit from
prevention counselling that included discussion of the microbicide gel.
But, said Dr Stephen Becker, “the idea of doing sex education
in schools and distributing products for HIV prevention is not a
straightforward path and will take a great deal of pushing.”
Nevertheless, it highlights one of the key discussions about
niches for prevention products that will need to take place: as well as
thinking about the characteristics of populations most likely to benefit, a
clear strategy will also be needed for overcoming the social, legal and health
system barriers that could prevent maximum impact of microbicides.
While circumcising male adolescents is easy and socially
acceptable, social and legal constraints on the sexuality of women will
continue to undermine the central promise of microbicides – a prevention tool
to empower women – unless confronted head-on.
This news report is also available in French.